GRANICIP 3ML INJ. VIAL.

About

Granisetron is a highly selective serotonin 5-HT3 receptor antagonist, primarily used for the prevention and treatment of chemotherapy-induced nausea and vomiting (CINV) and radiotherapy-induced nausea and vomiting (RINV). Chemotherapy and radiation therapy can release serotonin from enterochromaffin cells in the gastrointestinal tract, which then stimulates 5-HT3 receptors on vagal afferent nerves, leading to the activation of the vomiting center in the brain. Granisetron works by blocking these 5-HT3 receptors, thereby preventing the initiation of the emetic reflex.

Its high selectivity for the 5-HT3 receptor contributes to its efficacy and a relatively favorable side effect profile compared to less selective antiemetics. Granisetron is particularly effective in managing both acute and delayed phases of CINV, making it a cornerstone in supportive care for cancer patients undergoing emetogenic treatments. The injectable form allows for rapid onset of action, which is crucial in acute settings, providing prompt relief from distressing symptoms.

Uses

• Prevention of acute and delayed chemotherapy-induced nausea and vomiting.
• Treatment of established chemotherapy-induced nausea and vomiting.
• Prevention of radiotherapy-induced nausea and vomiting.
• Post-operative nausea and vomiting (off-label in some regions).

Directions For Use

Administered intravenously by a healthcare professional, typically before chemotherapy or radiotherapy. Dosage is based on patient's condition and treatment regimen.

Benefits

• Highly effective in preventing chemotherapy-induced nausea and vomiting.
• Reduces the incidence and severity of radiotherapy-induced nausea and vomiting.
• Provides significant relief from emetic symptoms, improving patient comfort.
• Has a rapid onset of action when administered intravenously.
• Generally well-tolerated with a favorable safety profile.
• Helps patients maintain nutritional intake during cancer treatment.

Side Effects

• Headache
• Constipation
• Diarrhea
• Asthenia (weakness)
• Dizziness
• Insomnia
• Abdominal pain
• Fever
• Hypotension (low blood pressure)
• Bradycardia (slow heart rate)
• Allergic reactions (rash, anaphylaxis)
• QT prolongation (rare)

Safety Measures

• Alcohol - No known direct interaction, but alcohol can cause gastrointestinal upset and dehydration, which may worsen nausea or side effects.
• Pregnancy - Use only if clearly needed, as animal studies show some risk, and human data are limited. Consult a physician.
• Breastfeeding - Use with caution; it is unknown if granisetron is excreted in human milk. A decision should be made to discontinue nursing or the drug.
• Liver - No dose adjustment is generally needed for hepatic impairment, but use with caution in severe cases.
• Kidney - No dose adjustment is generally needed for renal impairment.
• Lung - No specific lung-related safety concerns. However, monitor for any unusual respiratory symptoms in severely ill patients.

Disclaimer

MedEHub is committed to delivering reliable, expert-reviewd information to help consumers make informed health decisions. However, the content provided on this website is for informational purposes only and is not intended to replace professional medical advice, diagnosis or treatment.

Always consult your doctor for any medical concerns, and discuss your questions about health conditions or medications with a qualified healthcare professional. Do not ignore or delay seeking professional medical advice based on information found on Med E Hub.

Our goal is to complement, not replace, the essential doctor-patient relationship.